Oral bioavailability, tissue distribution and depletion of flumequine in the food producing animal, chicken for fattening

Food and Chemical Toxicology

Volumn 46, Issue 2, 2008, Pages 662-670

  Anadon A ^a   Martinez M A ^a   Martinez M ^a   De La Cruz, C ^a   Diaz M J ^a   Martinez Larranaga M R ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Chickens for fattening; Flumequine; Kinetics; Tissue depletion; Withdrawal time

Indexed keywords

7 HYDROXYFLUMEQUINE; DRUG METABOLITE; FAT; FLUMEQUINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONOLOGY; COMPARTMENT MODEL; CONTROLLED STUDY; DEPLETION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG MUSCLE LEVEL; FOOD; KIDNEY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NONHUMAN; POULTRY; SINGLE DRUG DOSE; SKIN; TISSUE LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHICKENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUOROQUINOLONES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; TISSUE DISTRIBUTION;

ANIMALIA; GALLUS GALLUS;

EID: 37349128848     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2007.09.086     Document Type: Article

References (51)

1. Anadón A., Martínez-Larrañaga M.R., Velez C., Díaz M.J., and Bringas P. Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. Am. J. Vet. Res. 53 (1992) 2084-2089
2. Anadón A., Martínez-Larrañaga M.R., Díaz M.J., Bringas P., Martínez M.A., Fernández-Cruz M.L., Fernández M.C., and Fernández R. Pharmacokinetics and residues of enrofloxacin in chickens. Am. J. Vet. Res. 56 (1995) 501-506
3. Anadón A., Martínez-Larrañaga M.R., Díaz M.J., Martínez M.A., Frejo M.T., Martínez M., Tafur M., and Castellano V.J. Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens. Am. J. Vet. Res. 63 (2002) 927-933
4. Atef M., El-Gendi A.Y.I., El-Sayed M.G.A., and Ramadan A. Some pharmacokinetics and microbiologic aspects of flumequine in chickens. Arch. Gefluegelk. 51 (1987) 88-92
5. Baggot J.D. Distribution of antimicrobial agents in normal and diseased animals. J. Am. Vet. Med. Assoc. 176 (1980) 1085-1090
6. Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. S1 (1993) 6-8
7. Dalla Costa T., and Derendorf H. AUIC - A general target for the optimisation of doping regimens of antibiotics?. Ann. Pharmacother. 30 (1996) 1024-1031
8. Delmas J.M., Chapel A.M., Gaudin V., and Sanders P. Pharmacokinetics of flumequine in sheep after intravenous and intramuscular administration: bioavailability and tissue residue studies. J. Vet. Pharmacol. Ther. 20 (1997) 249-257
9. Dorrestein G.M., Van Gogh H., Buitelaar M.N., and Nouws J.F.M. Clinical pharmacology and pharmacokinetics of flumequine after intravenous, intramuscular and oral administration in pigeons (Columba livia). J. Vet. Pharmacol. Ther. 6 (1983) 281-292
10. Drusano G.L., Johnson D.E., Rosen M., and Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37 (1993) 483-490
11. EMEA (The European Agency for the Evaluation of Medicinal Products) 1995. Note for Guidance: Approach Towards Harmonisation of Withdrawal Periods. EMEA/CVMP/036/95, pp. 1-37.
12. EMEA (The European Agency for the Evaluation of Medicinal Products) 1998. Guideline on Validation of Analytical Procedures: Methodology (VICH GL2). CVMP/VICH/591/98-FINAL, pp. 1-10.
13. EMEA (The European Agency for the Evaluation of Medicinal Products) 2002. Committee for Veterinary Medicinal Products. Summary Report on Flumequine (Extension to all food producing species). EMEA/MRL/823/02-FINAL, pp. 1-2.
14. EMEA (The European Agency for the Evaluation of Medicinal Products) 2002 Updated Application Software relating to Note for Guidance on Approach towards Harmonisation of Withdrawal Periods for Meat (see CVMP/036/95). EMEA/CVMP/563/02, p. 1.
15. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37 (1993) 1073-1081
16. Gibaldi M., and Perrier D. Pharmacokinetics. second ed. (1982), Marcel Dekker Inc., New York
17. Goren E., De Jong W.A., and Doornenbal P. Pharmacokinetical aspects of flumequine and therapeutic efficacy in Escherichia coli infection in poultry. Avian Pathol. 11 (1982) 463-474
18. Greenwood D. Activity of flumequine against Escherichia coli: in vitro comparison with nalidixic and oxolinic acids. Antimicrob. Agents Chemother. 13 (1978) 479-483
19. Hansen M.K., and Horsberg T.E. Single-dose pharmacokinetics of flumequine in halibut (Hippoglossus hippoglossus) and turbot (Scophthalamus maximus). J. Vet. Pharmacol. Ther. 22 (1999) 122-126
20. Harrison L.I., Scuppan D., Rohlfing S.R., Hansen A.R., Gester J.F., Hansen C.S., Funk M.L., and Ober R.E. Disposition of radiolabeled flumequine in rat and dog. Drug Metab. Dispos. 14 (1986) 555-558
21. Madaras-Kelly K.J., Ostergaard B.E., Baeker Hovde L., and Rostchafer J.C. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40 (1996) 627-632
22. Marchbanks C.R., McKiel Jr., Gilbert D.H., Robillard N.J., Painter B., Zinner S.H., and Dudley M.N. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob. Agents Chemother. 37 (1993) 1756-1763
23. Meijer B.A., Ceyssens K.G., De Jong W.T., and De Greve B.I. Bioavailability of flumequine after semisimultaneous administration to veal calves. Pharm. Res. 11 (1994) 117-121
24. Meinen J.B., McClure J.T., and Rosin C.H. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am. J. Vet. Res. 56 (1995) 1219-1224
25. Mevius D.J., Breukink H.J., Guelen P.J.M., Jansen T., and De Greve B. Pharmacokinetics, metabolism and renal clearance of flumequine in veal calves. J. Vet. Pharmacol. Ther. 13 (1990) 159-169
26. Mevius D.J., Breukink H.J., and Van Miert A.S.J.P.A.M. In vitro activity of flumequine in comparison with several other antimicrobial agents against five pathogens isolated in calves in The Netherlands. Vet. Q. 12 (1990) 212-220
27. Neuman M. Flumequine. Drugs Today 14 (1978) 365-566
28. Petersar L.R. Quinolone resistance in clinical practice: occurrence and importance. In: Hooper D.C., and Wolfson J.S. (Eds). Quinolone Antimicrobial Agents. second ed. (1993), American Society of Microbiology, Washington, DC 119-137
29. Pijpers A., Van Klingeren B., Schoevers E.J., Verheijden J.H.M., and Van Miert A.S.J.P.A.M. In vitro activity of five tetracyclines and some other antimicrobial agents against four porcine respiratory tract pathogens. J. Vet. Pharmacol. Ther. 12 (1989) 267-276
30. Raemdonck D.L., Tanner A.C., Tolling S.T., and Michener S.L. In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials. Avian Dis. 36 (1992) 964-967
31. Riegelman S., and Collier P.S. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm. 8 (1980) 509-534
32. Rogstad A., Ellingsen O.F., and Syvertsen C. Pharmacokinetics and bioavailability of flumequine and oxolinic acid after various routes of administration to Atlantic salmon in seawater. Aquaculture 110 (1993) 207-220
33. Ruiz-Garcia A., Berejo M., Merino V., Sanchez-Castaño G., Freixas J., and Garrigues T.M. Pharmacokinetics, bioavailability and absorption of flumequine in the rat. Eur. J. Pharm. Biopharm. 48 (1999) 253-258
34. Samaha I., Ellerbroek L., Ebrecht A., Matthes S., and Wenzel S. Pharmacokinetics and tissue residues of flumequine in chickens. Arch. Lebensmittelhyg. 42 (1991) 33-36
35. Samuelsen O.B. Efficacy of bath-administered flumequine and oxolinic acid in the treatment of vibriosis in small Atlantic halibut. J. Aquat. Anim. Health 9 (1997) 127-131
36. Schentag J.J. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationship between serum concentrations, MIC values, and bacterial eradication in patients with Gram-negative pneumonia. Scand J. Infect. Dis. S74 (1991) 218-234
37. Schentag J.J., Nix D.E., and Forrest A. Pharmacodynamics of the fluoroquinolones. In: Hooper D.C., and Wolfson J.S. (Eds). Quinolone Antimicrobial Agents. second ed. (1993), American Society for Microbiology, Washington, DC 259-271
38. Schentag J.J. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin. Infect. Dis. 31 Suppl.2 (2000) 40-44
39. Schuppan D., Harrison L.I., Rohlfing S.R., Miller H.L., Funk M.L., Hansen C.S., and Ober R.E. Plasma and urine levels of flumequine and 7-hydroxyflumequine following single and multiple oral dosing. J. Antimicrob. Chemother. 15 (1985) 337-343
40. Schwartz G. Estimating the dimension of a model. Ann. Stat. 6 (1978) 461-464
41. Sheiner L.B. ELSFIT a program for the extended least squares fit to individual pharmacokinetic data. A technical report of the Division of Clinical Pharmacology (1981), University of California Press, San Francisco
42. Steer C.R., Huby C.L., Ball E.T., Wilson A.M.M., and Gray J.A. Clinical and laboratory studies with R802, a new synthetic quinolone, in urinary tract infection. J. Antimicrob. Chemother. 7 (1981) 643-648
43. Sullivan M.C., Cooper B.W., Nightingale C.H., Quintiliani R., and Lawlor M.T. Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumonia by using a mouse protection model. Antimicrob. Agents Chemother. 37 (1993) 234-239
44. Villa R., Cagnardi P., Sonzogni O., and Carli S. Flumequine in the goat: pharmacokinetics after intravenous and intramuscular administration. Vet. Res. Commun. 29 (2005) 689-698
45. Villa R., Cagnardi P., Acocella F., Massi P., Anfossi P., Asta F., and Carli S. Pharmacodynamics and pharmacokinetics of flumequine in pigs after single intravenous and intramuscular administration. Vet. J. 170 (2005) 101-107
46. Vree T.B., Van Ewijk-Beneken Kolmer E.W., and Nouws J.F. Direct-gradient high-performance liquid chromatographic analysis and preliminary pharmacokinetics of flumequine and flumequine acyl glucuronide in humans: effect of probenecid. J. Chromatogr. 579 (1992) 131-141
47. Wagner J.G. Fundamentals of Clinical Pharmacokinetics. first ed. (1975), Drug Intelligence Publications, Hamilton, Illinois
48. Wagner J.G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J. Pharmacokinet. Biopharm. 4 (1976) 443-467
49. Yamaoka K., Nakagawa T., and Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6 (1978) 165-175
50. Yorke J.C., and Froc P. Quantitation of nine quinolones in chicken tissues by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. A 882 (2000) 63-77
51. Ziv G., Soback S., Bor A., and Kurtz B. Clinical pharmacokinetics of flumequine in calves. J. Vet. Pharmacol. Ther. 9 (1986) 171-182